Montelukast (DB00471): A Comprehensive Pharmacological, Clinical, and Regulatory Monograph

I. Executive Summary

Montelukast is a selective and orally active cysteinyl leukotriene receptor antagonist (CysLT1), developed by Merck & Co. and first marketed under the brand name Singulair. As a small molecule drug, it represents a targeted therapeutic approach to inflammatory airway diseases by blocking the pro-inflammatory cascade mediated by leukotrienes. Its established clinical utility lies in the prophylaxis and chronic treatment of asthma, the prevention of exercise-induced bronchoconstriction (EIB), and the symptomatic relief of both seasonal and perennial allergic rhinitis. In the therapeutic hierarchy, Montelukast is generally positioned as an alternative or adjunctive therapy. For asthma management, it is considered less effective than inhaled corticosteroids (ICS), which remain the first-line standard of care, but serves as a valuable option for patients with adherence issues to inhalers, specific asthma phenotypes such as aspirin-exacerbated respiratory disease, or those with a significant fear of steroids. In allergic rhinitis, its efficacy is comparable to second-generation antihistamines but inferior to intranasal corticosteroids.

The clinical profile of Montelukast is fundamentally defined by a significant safety concern: the risk of serious neuropsychiatric events. This risk prompted the U.S. Food and Drug Administration (FDA) to issue its most stringent warning—a Boxed Warning—in March 2020, a measure echoed by regulatory bodies globally, including the European Medicines Agency (EMA). The spectrum of these adverse events is broad, ranging from agitation, depression, and sleep disturbances to suicidality and completed suicide. These events can occur in patients with or without a prior psychiatric history and may persist after drug discontinuation. This safety profile has profoundly reshaped the drug's risk-benefit assessment, leading the FDA to recommend that for allergic rhinitis, its use should be restricted to patients who have had an inadequate response to or are intolerant of other therapies.

Pharmacologically, Montelukast's therapeutic effects are derived from its high-affinity, selective antagonism of the CysLT1 receptor in the airways. However, the molecule's ability to cross the blood-brain barrier and interact with CysLT1 receptors within the central nervous system provides a plausible mechanistic basis for its neuropsychiatric side effects. Its pharmacokinetic profile is characterized by extensive hepatic metabolism via multiple cytochrome P450 enzymes (CYP3A4, CYP2C9, and notably CYP2C8), creating a vulnerability to significant drug-drug interactions with potent enzyme inhibitors (e.g., gemfibrozil) and inducers (e.g., rifampicin, phenobarbital).

In conclusion, Montelukast is a clinically useful but complex medication. Its prescription demands a highly individualized approach, prioritizing careful patient selection and comprehensive counseling. The paramount importance of discussing the neuropsychiatric risks with patients and caregivers cannot be overstated. Clinical use must adhere strictly to current regulatory guidance, particularly the restricted role in mild allergic rhinitis, to ensure that its benefits outweigh its substantial and well-documented risks.

II. Chemical and Physical Properties

Montelukast is a synthetic, orally active small molecule drug identified chemically as a member of the quinoline class of compounds. Structurally, it is further characterized as a monocarboxylic acid and an aliphatic sulfide.[1] It was developed by Merck and first received clinical use approval from the U.S. Food and Drug Administration (FDA) in 1998 under the brand name Singulair.[1] The molecule's design incorporates specific functional groups that enable its targeted pharmacological activity as a leukotriene receptor antagonist.

Structural and Chemical Data

The definitive identity of Montelukast is established through a consistent set of chemical and physical descriptors across multiple international databases and chemical suppliers.

• Chemical Structure: The two-dimensional structure of Montelukast is as follows: !(https://www.medkoo.com/images/product/Montelukast.png)
• Systematic Naming (IUPAC): The formal IUPAC name for the compound is 2-phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid.[1] An alternative formal name is 1-phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid.[4]
• Molecular Formula: The empirical formula for the free acid form of Montelukast is C35​H36​ClNO3​S.[1] The active pharmaceutical ingredient is typically formulated as its monosodium salt, Montelukast sodium, which has the molecular formula C35​H35​ClNNaO3​S.[6]
• Molecular Weight: The molecular weight of the free acid is approximately 586.2 g/mol.[1] The corresponding sodium salt has a molecular weight of 608.18 g/mol.[6]
• Physicochemical Properties:
• Appearance: Montelukast is a solid at room temperature.[2]
• Melting Point: The melting point is reported to be in the range of 145-148 °C.[2]
• Solubility: It demonstrates solubility in organic solvents such as dimethylformamide (DMF) and dimethyl sulfoxide (DMSO) at concentrations of approximately 2 mg/ml, but it is considered insoluble in ethanol and in aqueous solutions like phosphate-buffered saline (PBS) at a pH of 7.2.[2]
• Acidity (pKa): The predicted acid dissociation constant (pKa) for the carboxylic acid group is 4.76 ± 0.10, indicating it is a weak acid.[2]

The use of the sodium salt in pharmaceutical formulations is a critical aspect of the drug's design. Montelukast free acid, as a carboxylic acid, exhibits poor solubility in water, which would severely limit its dissolution in the gastrointestinal tract and subsequent absorption into the bloodstream after oral administration.[2] By converting the carboxylic acid to its corresponding monosodium salt, a process known as saltification, the molecule's aqueous solubility and dissolution rate are significantly enhanced. This deliberate formulation strategy is essential for achieving adequate oral bioavailability, allowing the drug to be effective when taken by mouth. This highlights a fundamental principle of pharmaceutical development: the clinical success of a drug often depends not only on the intrinsic activity of the molecule but also on its formulation into a stable and bioavailable dosage form.[6]

Table 2.1: Comprehensive Chemical and Physical Identifiers of Montelukast

Identifier	Value	Source(s)
Common Name	Montelukast	3
DrugBank ID	DB00471	1
CAS Number (Free Acid)	158966-92-8	1
CAS Number (Sodium Salt)	151767-02-1	1
IUPAC Name	2-phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid	1
Molecular Formula (Free Acid)	C35​H36​ClNO3​S	1
Molecular Formula (Sodium Salt)	C35​H35​ClNNaO3​S	6
Molecular Weight (Free Acid)	586.2 g/mol	1
Molecular Weight (Sodium Salt)	608.18 g/mol	6
InChIKey	UCHDWCPVSPXUMX-TZIWLTJVSA-N	1
SMILES	CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O	1
PubChem CID	5281040	11
ChEBI ID	CHEBI:50730	1
ChEMBL ID	CHEMBL787	1
KEGG ID	D08229	1
Melting Point	145-148 °C	2
Solubility	DMF: 2 mg/ml; DMSO: 2 mg/ml; Ethanol: insoluble	2

III. Clinical Pharmacology

A. Mechanism of Action (Pharmacodynamics)

The pharmacodynamic effects of Montelukast are rooted in its targeted intervention in the leukotriene inflammatory pathway. Its clinical efficacy in asthma and allergic rhinitis is a direct result of antagonizing specific receptors involved in this cascade, while its most significant adverse effects can also be traced back to this same mechanism acting within the central nervous system.

The Leukotriene Pathway

The synthesis of leukotrienes begins with the release of arachidonic acid from cell membrane phospholipids. The enzyme 5-lipoxygenase (5-LOX) then metabolizes arachidonic acid to produce a class of potent inflammatory mediators, most notably the cysteinyl leukotrienes (CysLTs): leukotriene C4 (LTC4​), leukotriene D4 (LTD4​), and leukotriene E4 (LTE4​).[13] These CysLTs are released from various immune cells, including mast cells and eosinophils, which are central to allergic inflammation.[7]

Once released, CysLTs exert their effects by binding to specific receptors. The primary target relevant to Montelukast's action is the cysteinyl leukotriene type-1 (CysLT1) receptor. This receptor is prominently expressed in the human airway on cells such as airway smooth muscle cells and airway macrophages, as well as on other pro-inflammatory cells like eosinophils.[7] The binding of leukotrienes to the CysLT1 receptor triggers a cascade of events that are hallmarks of the pathophysiology of asthma and allergic rhinitis, including bronchoconstriction, increased microvascular permeability leading to airway edema, enhanced mucus secretion, and the recruitment of inflammatory cells (particularly eosinophils) into the airway tissues.[11]

Primary Peripheral Mechanism

Montelukast functions as a potent, selective, and orally active antagonist of the CysLT1 receptor.[3] It binds with high affinity to this receptor, thereby competitively inhibiting the physiological actions of its natural ligands,

LTD4​, LTC4​, and LTE4​.[3] A key feature of its pharmacological profile is its high selectivity; it does not exhibit any agonist activity and does not meaningfully interact with other pharmacologically important airway receptors, such as prostanoid, cholinergic, or beta-adrenergic receptors, ensuring its effects are focused on the leukotriene pathway.[3] Laboratory studies have quantified this selectivity, showing a half-maximal inhibitory concentration (

IC50​) for the human CysLT1 receptor of approximately 4.9 nM, compared to an IC50​ of over 10,000 nM for the CysLT2 receptor.[4]

The physiological consequences of this targeted blockade are clinically significant. In asthma, by preventing CysLTs from binding to their receptors, Montelukast directly counteracts the key pathological processes of the disease. It reduces airway edema, promotes the relaxation of airway smooth muscle (bronchodilation), and diminishes the inflammatory cell infiltrate.[11] This bronchodilatory effect can be observed as soon as within two hours of oral administration, and doses as low as 5 mg have been shown to substantially block bronchoconstriction induced by inhaled

LTD4​.[3] In allergic rhinitis, where CysLTs are released from the nasal mucosa after allergen exposure and contribute to symptoms of nasal obstruction, Montelukast's antagonism helps to alleviate these symptoms.[13]

At a cellular level, the CysLT1 receptor is a G-protein coupled receptor. Its blockade by Montelukast prevents the activation of its associated G-protein. This in turn halts the downstream signaling cascade involving the enzyme phospholipase C, thereby reducing the production of secondary messengers inositol triphosphate (IP3) and diacylglycerol (DAG). The ultimate effect is a decrease in intracellular calcium levels, which leads to reduced plasma exudation, diminished mucus secretion, relief of bronchoconstriction, and a reduction in eosinophil recruitment.[20]

Central Nervous System Effects and Neuropsychiatric Mechanism

While Montelukast's intended therapeutic action is peripheral, its most concerning adverse effects are neuropsychiatric, a phenomenon that can be explained by the drug's ability to access the central nervous system (CNS). Although rat studies indicated minimal distribution across the blood-brain barrier (BBB), the fact that it crosses at all is clinically significant.[13] This penetration allows the drug to interact with CysLT1 receptors that are also expressed within the brain, particularly in regions implicated in mood regulation, anxiety, and cognitive function.[14]

This interaction with central CysLT1 receptors represents an "off-target" effect in the context of treating respiratory disease, but it is a direct extension of the drug's primary mechanism of action. Leukotrienes are not only peripheral inflammatory mediators but also play a role in neuroinflammatory processes and can modulate the function of key neurotransmitter systems, including serotonin, dopamine, and norepinephrine.[14] By blocking these central receptors, Montelukast may disrupt the delicate neurochemical homeostasis maintained by endogenous leukotrienes. This disruption of serotonergic and dopaminergic pathways could plausibly lead to the observed spectrum of neuropsychiatric symptoms, such as depression, anxiety, agitation, and sleep disturbances. This provides a direct pharmacodynamic link between the drug's mechanism and its most severe side effects, reframing these events not as an unrelated anomaly but as a potential consequence of the drug's fundamental pharmacology acting in an unintended location.

B. Pharmacokinetic Profile

The pharmacokinetic profile of Montelukast describes its journey through the body—absorption, distribution, metabolism, and excretion (ADME)—which dictates its dosing regimen and potential for drug interactions.

Absorption

Montelukast is rapidly absorbed from the gastrointestinal tract following oral administration.[3] The rate and extent of absorption are influenced by the specific formulation and the presence of food.

• 10-mg film-coated tablet (standard adult dose): When administered to adults in a fasted state, the mean peak plasma concentration (Cmax​) is achieved in 3 to 4 hours (Tmax​). The mean oral bioavailability is 64%. The presence of a standard meal does not significantly affect the bioavailability or Cmax​ of this formulation, allowing for dosing without regard to meals.[13]
• 5-mg chewable tablet: In fasted adults, the Cmax​ is reached more quickly, in 2 to 2.5 hours. The mean oral bioavailability in the fasted state is higher at 73%, but this is reduced to 63% when administered with a standard meal, indicating a moderate food effect.[7]
• 4-mg oral granules: This formulation is bioequivalent to the 4-mg chewable tablet. While co-administration with applesauce has no significant effect, a high-fat meal does not alter the total drug exposure (AUC) but does decrease the peak concentration (Cmax​) by 35% and significantly prolongs the time to reach it (Tmax​) from approximately 2.3 hours to 6.4 hours.[13]

Distribution

Once absorbed, Montelukast is extensively distributed but largely confined to the plasma and extracellular fluids. It is more than 99% bound to plasma proteins, primarily albumin.[13] This high degree of protein binding limits its free concentration in the blood. The steady-state volume of distribution (

Vd​) is small, averaging 8 to 11 liters in healthy adults, which is consistent with its limited tissue penetration.[13] As previously noted, animal studies indicate minimal, but not absent, distribution across the blood-brain barrier.[13]

Metabolism

Montelukast undergoes extensive hepatic (liver) metabolism before excretion.[3] This metabolic clearance is a critical determinant of its duration of action and its potential for interactions with other drugs.

• Enzymatic Pathways: The metabolism is primarily carried out by the cytochrome P450 (CYP) system of enzymes. The key isoenzymes involved are CYP3A4, CYP2C9, and CYP2C8, with evidence suggesting that CYP2C8 plays a particularly significant role.[3]
• Metabolites: At therapeutic doses, the metabolites of Montelukast are generally present at concentrations too low to be detected in the plasma at steady state, suggesting they do not contribute significantly to the drug's therapeutic or toxic effects.[13]
• Enzyme Inhibition Potential: In laboratory (in vitro) studies, Montelukast was shown to be a potent inhibitor of the CYP2C8 enzyme. However, this finding did not translate to a clinical effect. In vivo studies demonstrated that Montelukast does not inhibit CYP2C8 at therapeutic concentrations, a crucial distinction that means it is not expected to alter the metabolism of other drugs that are substrates for this enzyme, like rosiglitazone or paclitaxel.[10]

The reliance of Montelukast on multiple major CYP enzymes for its clearance creates a point of vulnerability. Its plasma concentration can be significantly altered by co-administered drugs that either induce or inhibit these enzymes. Strong enzyme inducers, such as the anticonvulsants phenobarbital and phenytoin or the antibiotic rifampicin, can accelerate the metabolism of Montelukast, leading to lower-than-expected plasma levels and a potential for reduced therapeutic efficacy.[10] Conversely, potent inhibitors of these pathways can slow down its metabolism, leading to elevated plasma concentrations and an increased risk of adverse effects. A prime example is the co-administration with gemfibrozil, a strong inhibitor of both CYP2C8 and CYP2C9, which was shown in a clinical study to increase the systemic exposure (AUC) of Montelukast by a dramatic 4.4-fold.[10] This highlights that careful medication reconciliation is essential for patients taking Montelukast to avoid clinically significant drug interactions that could compromise either safety or efficacy.

Excretion

The elimination of Montelukast and its metabolites from the body occurs almost exclusively via the bile and subsequent excretion in the feces. Following an oral dose of radiolabeled Montelukast, 86% of the radioactivity was recovered in fecal collections over five days, while less than 0.2% was found in the urine.[13] This biliary excretion pathway means that renal function has a negligible impact on the drug's clearance.

• Plasma Clearance: The average plasma clearance of Montelukast in healthy adults is approximately 45 mL/min.[13]
• Half-Life: The mean plasma half-life (t1/2​) in healthy young adults ranges from 2.7 to 5.5 hours.[13] This relatively short half-life supports a once-daily dosing regimen.

Pharmacokinetics in Special Populations

The behavior of Montelukast has been studied in various populations to determine if dose adjustments are necessary.

• Linearity: The pharmacokinetics are nearly linear for oral doses up to 50 mg, meaning that an increase in dose leads to a proportional increase in plasma concentration.[13]
• Gender: Clinical studies have found little to no effect of gender on the pharmacokinetic parameters of Montelukast.[10]
• Elderly: The pharmacokinetic profile in elderly adults is similar to that in younger adults. While the plasma half-life may be slightly longer, no dosage adjustment is required.[6]
• Renal Impairment: Because Montelukast and its metabolites are not excreted via the urine, no dosage adjustment is needed for patients with any degree of renal insufficiency.[10]
• Hepatic Impairment: In patients with mild-to-moderate hepatic insufficiency accompanied by clinical evidence of cirrhosis, the metabolism of Montelukast is decreased. This results in an approximately 41% higher mean AUC and a slightly prolonged elimination half-life (mean of 7.4 hours). Despite this change, no dosage adjustment is recommended for patients with mild-to-moderate hepatic impairment. The drug's pharmacokinetics have not been evaluated in patients with severe hepatic impairment.[10]

Table 3.1: Summary of Key Pharmacokinetic Parameters for Montelukast 10 mg

Parameter	Formulation / Condition	Population	Value	Source(s)
Tmax​ (Time to Peak Concentration)	10 mg Film-Coated Tablet (Fasted)	Adult	3 - 4 hours	13
	5 mg Chewable Tablet (Fasted)	Adult	2 - 2.5 hours	13
	4 mg Oral Granules (Fasted)	Pediatric	~2.3 hours	13
	4 mg Oral Granules (High-Fat Meal)	Pediatric	~6.4 hours	13
Oral Bioavailability (F)	10 mg Film-Coated Tablet (Fasted)	Adult	64%	13
	5 mg Chewable Tablet (Fasted)	Adult	73%	13
	5 mg Chewable Tablet (Fed)	Adult	63%	13
Plasma Protein Binding	N/A	Adult	>99%	13
Volume of Distribution (Vd​)	Steady State	Adult	8 - 11 Liters	13
Plasma Half-Life (t1/2​)	Oral or IV	Healthy Adult	2.7 - 5.5 hours	13
Metabolism	N/A	Human	Extensive Hepatic (CYP3A4, 2C9, 2C8)	3
Excretion	N/A	Human	>86% Fecal, <0.2% Renal	13

IV. Clinical Efficacy and Therapeutic Applications

Montelukast has secured a distinct, albeit carefully defined, role in the management of common inflammatory airway diseases. Its efficacy has been established through numerous clinical trials, leading to specific FDA-approved indications. However, its therapeutic position is best understood through a comparative analysis against standard-of-care treatments and in light of its significant safety considerations.

A. Approved Indications

The U.S. Food and Drug Administration (FDA) has approved Montelukast for three primary indications, with specific age restrictions for each.

• Prophylaxis and Chronic Treatment of Asthma: Montelukast is indicated for the long-term control and prevention of asthma symptoms in adults and pediatric patients aged 12 months and older.[3] It is not a rescue medication and should not be used to treat an acute asthma attack. Its role is typically as an add-on therapy for patients inadequately controlled on inhaled corticosteroids (ICS) or as an alternative monotherapy for those with mild persistent asthma who are unable or unwilling to use ICS.[1] Clinical studies have demonstrated that it can be used either alone or concomitantly with other maintenance treatments, where it can provide an additive effect and potentially allow for a reduction in the required ICS dose while maintaining clinical stability.[3]
• Prevention of Exercise-Induced Bronchoconstriction (EIB): For patients aged 6 years and older, Montelukast is approved for the prevention of bronchospasm triggered by physical exertion.[24] A single dose is administered at least two hours prior to exercise to provide protection.[23]
• Allergic Rhinitis (Seasonal and Perennial): Montelukast is indicated for the relief of symptoms associated with seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and for perennial allergic rhinitis (PAR) in patients 6 months of age and older.[25] However, this indication carries a crucial regulatory restriction. Due to the risk of serious neuropsychiatric events, the FDA explicitly advises that Montelukast should be reserved for patients with allergic rhinitis who have not achieved an adequate response to, or cannot tolerate, other standard allergy medications.[11] This significantly limits its use as a first-line agent for this common condition.

B. Comparative Efficacy Analysis

Evaluating the clinical utility of Montelukast requires comparing its effectiveness against the primary therapeutic alternatives for its main indications.

Montelukast vs. Inhaled Corticosteroids (ICS) for Asthma

The consensus from major international treatment guidelines, including the Global Initiative for Asthma (GINA) and the British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS-SIGN), is unequivocal: inhaled corticosteroids are the preferred first-line controller therapy for persistent asthma in both children and adults.[19] Leukotriene receptor antagonists (LTRAs) like Montelukast are consistently positioned as an alternative or add-on therapy.

This recommendation is supported by a large body of evidence from meta-analyses and head-to-head clinical trials. These studies have repeatedly shown that low-dose ICS are superior to Montelukast in improving key asthma outcomes, including lung function (as measured by forced expiratory volume in 1 second, FEV1​), reducing the frequency of severe exacerbations that require systemic corticosteroids, and improving overall day-to-day asthma control.[32] For instance, a major pediatric study (the PACT study) concluded that treatment with the ICS fluticasone resulted in 42 more asthma control days per year compared to treatment with Montelukast.[33]

Despite the clear evidence of ICS superiority in population-level studies, Montelukast maintains a relevant niche in asthma management. The concept of "superior on average" does not preclude the existence of individual patients who may derive significant benefit from LTRA therapy. There is considerable inter-individual variability in the response to both ICS and Montelukast, meaning that a treatment that is optimal for the average patient may not be optimal for all.[19] Furthermore, practical barriers to ICS use are common and can limit their real-world effectiveness. These include patient or parental "steroid phobia," difficulties with proper inhaler technique (especially in young children), and cost.[19] The simple, once-daily oral tablet formulation of Montelukast offers a significant advantage in convenience and adherence for these specific patient groups.[32]

Moreover, certain asthma phenotypes appear to be more responsive to leukotriene modulation. Montelukast has demonstrated particular utility in patients whose primary trigger is exercise (EIB) and in young children with viral-induced wheezing.[19] It is also considered a cornerstone therapy for individuals with aspirin-exacerbated respiratory disease (AERD), a specific syndrome characterized by asthma, nasal polyps, and a hypersensitivity to aspirin and other NSAIDs, where leukotriene overproduction is a central pathophysiological mechanism.[14] Therefore, Montelukast's therapeutic role is not as a direct competitor to ICS for all patients with persistent asthma, but rather as a valuable second-line or alternative tool for specific, well-defined clinical scenarios and patient profiles.

Montelukast vs. Antihistamines for Allergic Rhinitis

For the treatment of allergic rhinitis, Montelukast is considered a viable therapeutic option. As a monotherapy, its efficacy in controlling symptoms like sneezing, rhinorrhea, and nasal itching is generally considered to be equivalent to that of second-generation antihistamines such as loratadine and cetirizine.[36] However, it is less effective than intranasal corticosteroids (e.g., fluticasone, mometasone), which remain the most effective single-agent therapy for moderate-to-severe allergic rhinitis.[36]

Some studies have explored combination therapy, suggesting that adding an antihistamine to Montelukast may provide an additive benefit, with some results indicating that the combination can approach the efficacy of intranasal corticosteroids.[36] However, the evidence on this point is equivocal, as other well-controlled studies have failed to demonstrate a statistically significant advantage of combination therapy over either agent used alone.[36] From a cost-effectiveness standpoint, analyses have generally shown Montelukast to be a less favorable option than antihistamines. For example, studies comparing it to levocetirizine found that Montelukast had a higher cost per clinically relevant improvement in quality-of-life scores, making the antihistamine the more cost-effective choice.[39]

The clinical positioning of Montelukast for allergic rhinitis is a clear example of how a drug's safety profile can override its efficacy data. While effective, its use is severely curtailed by the FDA's recommendation to restrict it to second- or third-line therapy.[29] This decision stems from a critical regulatory risk-benefit analysis. Allergic rhinitis, while significantly impacting quality of life, is not a life-threatening condition. A wide array of alternative treatments, including numerous antihistamines and intranasal steroids, are available that are both effective and possess long-established, favorable safety profiles.[29] Given that Montelukast carries a risk of severe, potentially life-threatening neuropsychiatric side effects, the FDA concluded that for a mild-to-moderate, non-fatal condition like allergic rhinitis, the potential benefits of Montelukast do not outweigh its serious risks when safer alternatives exist. This demonstrates a core principle of modern pharmacovigilance: the acceptable level of risk is directly proportional to the severity of the disease being treated and the availability of safer therapeutic options.

C. Off-Label and Investigational Uses

Beyond its approved indications, Montelukast has been explored for other inflammatory conditions, though the evidence supporting these uses is generally weak or inconsistent.

• Chronic Urticaria (Hives): Montelukast has been studied as an off-label add-on therapy for patients with chronic idiopathic urticaria (CIU) who are refractory to standard antihistamine treatment.[41] The results from clinical trials have been conflicting. Some randomized trials and case series have reported benefits, with a subset of patients achieving complete symptom clearance.[41] In contrast, other well-designed, placebo-controlled trials found that adding Montelukast to an antihistamine provided no additional benefit compared to the antihistamine alone.[42] Consequently, major clinical guidelines from allergy and immunology societies provide only weak recommendations for its use in this setting, citing the low quality and inconsistency of the available evidence.[42]
• Atopic Dermatitis (Eczema): Due to the recognized role of leukotrienes in allergic inflammation, LTRAs like Montelukast have been investigated as a potential treatment for atopic dermatitis.[44] The overall evidence remains weak and inconclusive. A 2018 Cochrane review concluded that there was limited, low-quality evidence to support its efficacy.[47] While some small trials have suggested a modest benefit, particularly in reducing itching (pruritus) or disease severity scores in adults, larger and more robust trials have failed to show a significant difference between Montelukast and placebo.[45] At present, it is not recommended as a standard therapy and lacks FDA approval for this indication.[45]
• Other Investigational Uses: There are reports of Montelukast being used off-label for a variety of other conditions, including chronic obstructive pulmonary disease (COPD), acne, and obstructive sleep apnea (OSA).[49] It has also been explored in more specialized conditions like aspirin-exacerbated respiratory disease (AERD), cystic fibrosis, and even as a potential adjunctive treatment for behavioral symptoms in autism spectrum disorder, though the evidence for these uses is largely preliminary or anecdotal.[14]

Table 4.1: Comparative Efficacy Summary (Montelukast vs. Key Comparators)

Indication	Comparator	Efficacy Comparison	Key Endpoints	Source(s)
Chronic Asthma	Inhaled Corticosteroids (ICS)	ICS Superior	Lung Function (FEV1​), Exacerbation Rate, Symptom Control	32
Allergic Rhinitis	Second-Generation Antihistamines	Equivalent	Overall Symptom Control, Quality of Life	36
Allergic Rhinitis	Intranasal Corticosteroids	Intranasal Corticosteroids Superior	Nasal Symptom Control (especially congestion)	36

V. Safety, Tolerability, and Risk Management

The safety profile of Montelukast is complex, dominated by a significant risk of neuropsychiatric events that has led to major regulatory actions worldwide. Understanding this risk, along with its general adverse effect profile and potential for drug interactions, is critical for its safe clinical use.

A. The Black Box Warning: Neuropsychiatric Events

The most critical safety issue associated with Montelukast is its potential to cause a wide range of serious mental health side effects. These events can manifest in patients with or without a pre-existing psychiatric history, can be severe in nature, and in some cases, have been reported to persist even after the medication is discontinued.[11]

Spectrum of Reported Events

The neuropsychiatric events reported in association with Montelukast use are extensive and affect mood, behavior, cognition, and sleep. They include:

• Behavioral and Mood Changes: Agitation, aggressive behavior, hostility, irritability, restlessness, anxiety, and depression are among the most frequently cited events.[10]
• Cognitive and Perceptual Disturbances: Patients have reported attention problems, confusion, disorientation, memory impairment, and hallucinations (seeing or hearing things that are not there).[28]
• Sleep Disturbances: A prominent category of side effects includes insomnia (difficulty sleeping), abnormal or vivid dreams, nightmares, and somnambulism (sleepwalking).[10]
• Most Severe Outcomes: The most alarming risks are suicidal thinking and behavior (suicidality), and completed suicide. These have been reported in both adults and children.[10] An FDA review of its adverse event database from 1998 to 2019 identified 82 reports of suicide linked to the use of Montelukast.[31]

Regulatory Timeline and Global Response

The recognition of this risk evolved over more than a decade, culminating in stringent regulatory actions.

• 2008-2009: The FDA initiated its first formal investigations into the possibility of Montelukast-induced neuropsychiatric effects following post-marketing reports.[1]
• March 2020: In a landmark decision, the U.S. FDA mandated the addition of a Boxed Warning—its most prominent safety warning—to the prescribing information for Montelukast and all its generic versions.[11] This action was accompanied by a requirement for a new patient Medication Guide to be dispensed with every prescription, ensuring patients are directly informed of the risks.[22]
• European Medicines Agency (EMA): Paralleling the FDA's concerns, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended strengthening the warnings in 2019. Following further review, a new boxed warning was recommended for the product information across the European Union, a process that was finalized in April 2023.[51]
• Other Agencies: Other national regulatory bodies, such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA), have also conducted ongoing safety reviews in response to continued reporting of these adverse events.[55]

The FDA's 2020 decision to implement a Boxed Warning represents a significant evolution in regulatory philosophy. The action was taken despite the agency's acknowledgment that new safety data were limited.[29] The decision was instead based on a comprehensive re-evaluation of all available evidence, the input of a panel of outside experts, and a growing concern that previous, less prominent warnings were not effectively communicating the severity of the risk to prescribers and patients.[56] A key component of this action was the recommendation to restrict the drug's use in mild allergic rhinitis. The agency's rationale was that the potential benefits of using Montelukast for a non-life-threatening condition did not outweigh the risk of severe, potentially irreversible, or fatal neuropsychiatric harm, particularly when numerous safer and effective alternatives are widely available.[11] This case serves as a landmark in modern pharmacovigilance, demonstrating that a drug's risk-benefit profile can be formally re-adjudicated years after its initial approval based on a deeper understanding of the real-world impact of its risks. It prioritizes the prevention of harm from a rare but severe side effect over the convenience of treating a common, non-severe condition.

B. General Adverse Effect Profile

Beyond the neuropsychiatric events, Montelukast is associated with a range of other adverse effects.

• Common Side Effects: The most frequently reported adverse effects are generally mild and include headache, abdominal pain, cough, diarrhea, nausea, vomiting, fever, and mild rashes.[3] Upper respiratory tract infections are also commonly observed in clinical trials.[53]
• Less Common and Serious Side Effects:
• Hypersensitivity Reactions: Allergic reactions can occur, manifesting as skin rash, itching (pruritus), hives (urticaria), swelling of the deeper layers of skin (angioedema), and, in rare cases, severe, life-threatening anaphylaxis.[11]
• Hepatic Effects: Asymptomatic elevations in liver enzymes (transaminases) have been noted. While rare, more serious liver problems have been reported as a potential side effect.[11]
• Eosinophilic Conditions: In rare instances, patients taking Montelukast may present with systemic eosinophilia (an abnormally high level of eosinophils in the blood). This can sometimes be associated with the clinical features of vasculitis (inflammation of blood vessels) consistent with Churg-Strauss syndrome, a condition often treated with systemic corticosteroid therapy.[10]
• Overdose: The symptoms reported in cases of overdosage include abdominal pain, somnolence (drowsiness), thirst, headache, vomiting, and psychomotor hyperactivity.[3]

C. Drug-Drug Interactions

The potential for drug-drug interactions with Montelukast is primarily driven by its extensive metabolism via the cytochrome P450 enzyme system.

• Clinically Significant Interactions:
• CYP Enzyme Inducers: Co-administration of Montelukast with potent inducers of CYP enzymes can significantly accelerate its metabolism, leading to lower plasma concentrations and potentially reduced clinical efficacy. The most notable inducers are the anticonvulsants phenobarbital and phenytoin, and the antibiotic rifampicin. Studies have shown that co-administration with phenobarbital can decrease the area under the plasma concentration-time curve (AUC) for Montelukast by approximately 40%. Caution is advised when these drugs are used concomitantly, particularly in children.[10] Apalutamide, a strong CYP3A4 inducer, is another drug where co-administration should be avoided or closely monitored for loss of therapeutic effect.[23]
• CYP Enzyme Inhibitors: Conversely, co-administration with potent inhibitors of Montelukast's metabolic pathways can lead to significantly increased plasma concentrations and a heightened risk of toxicity. The most striking example is gemfibrozil, a potent inhibitor of both CYP2C8 and CYP2C9. A clinical drug-interaction study demonstrated that gemfibrozil increased the systemic exposure (AUC) of Montelukast by 4.4-fold.[10] While no specific dose adjustment is officially recommended, this profound interaction underscores a major risk for increased adverse effects.
• Other Interactions: Medical databases list a large number of moderate interactions, most of which are based on shared metabolic pathways.[3] Additionally, some sources suggest an increased risk of myopathy and rhabdomyolysis when Montelukast is combined with certain drugs like acipimox or alendronic acid.[3]

Table 5.1: Clinically Significant Drug-Drug Interactions with Montelukast

Interacting Drug/Class	Mechanism of Interaction	Effect on Montelukast	Clinical Recommendation/Management	Source(s)
Gemfibrozil	Potent inhibition of CYP2C8 and CYP2C9	Significantly increased plasma concentration (4.4-fold increase in AUC)	Caution advised. Monitor for adverse effects. Dose adjustment may be needed.	10
Rifampicin, Phenobarbital, Phenytoin	Strong induction of CYP3A4, CYP2C8, and/or CYP2C9	Decreased plasma concentration (~40% decrease in AUC with phenobarbital)	Caution advised, particularly in children. Monitor for reduced efficacy.	10
Apalutamide	Strong induction of CYP3A4	Decreased plasma concentration	Avoid or use alternative drug. If co-administration is necessary, monitor for loss of therapeutic effect.	23
Idelalisib, Fexinidazole, Tucatinib	Strong inhibition of CYP3A4	Increased plasma concentration	Avoid concomitant use or use alternative drug. May increase risk of adverse effects.	23

D. Contraindications and Precautions

While Montelukast has few absolute contraindications, several important precautions must be observed to ensure its safe use.

• Contraindications: The only absolute contraindication is a history of hypersensitivity to Montelukast or any of the excipients in the formulation.[18]
• Precautions:
• Acute Asthma Attacks: Montelukast is a controller medication and is not indicated for the treatment of acute asthma attacks or the reversal of bronchospasm. Patients must be educated on this point and must have a short-acting beta-agonist (SABA) inhaler available for rescue therapy.[11]
• Aspirin Sensitivity: Patients with known aspirin-exacerbated respiratory disease (AERD) should be advised to continue avoiding aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) while taking Montelukast.[3]
• Phenylketonuria (PKU): The 4 mg and 5 mg chewable tablet formulations contain aspartame, which is a source of phenylalanine. These formulations may be harmful to patients with phenylketonuria and should be used with caution.[6]
• Pre-existing Conditions: Given the risk of neuropsychiatric events, caution is warranted when prescribing Montelukast to patients with a history of psychiatric disorders. Similarly, caution should be exercised in patients with underlying liver disorders, although no dose adjustment is needed for mild-to-moderate impairment.[58]

VI. Dosage, Administration, and Formulations

The proper use of Montelukast requires strict adherence to dosing guidelines that are highly specific to the patient's age and the clinical indication being treated. The medication is available in several oral formulations to accommodate different age groups and patient preferences.

Available Formulations

Montelukast is commercially available in three distinct oral dosage forms:

• Film-coated Tablets: 10 mg strength, intended for adults and adolescents.[6]
• Chewable Tablets: 4 mg and 5 mg strengths, primarily for pediatric use.[3]
• Oral Granules: 4 mg per single-dose packet, designed for the youngest pediatric patients.[6]

Administration of Oral Granules

The 4-mg oral granule formulation has specific administration instructions to ensure proper dosing and stability. The packet should not be opened until immediately before use. Once opened, the full dose must be administered within 15 minutes. The granules can be given in one of three ways:

1. Administered directly into the mouth.
2. Dissolved in one teaspoonful (5 mL) of cold or room-temperature baby formula or breast milk.
3. Mixed with a spoonful of cold or room-temperature soft food. Based on stability studies, only applesauce, carrots, rice, or ice cream should be used for mixing.

The granules should not be mixed with or dissolved in any other liquids. If mixed with food or formula, the mixture must not be stored for future use.[25]

Dosing and Administration Guidelines

The following table consolidates the FDA-approved dosing and administration guidelines for Montelukast across all indications and age groups.

Table 6.1: Comprehensive Dosing and Administration Guide for Montelukast

Indication	Patient Age Group	Recommended Dose & Formulation	Frequency and Timing	Key Instructions	Source(s)
Asthma (Chronic Treatment)	Adults & Adolescents (≥15 years)	One 10-mg film-coated tablet	Once daily in the evening	Can be taken with or without food.	23
	Pediatric (6 to 14 years)	One 5-mg chewable tablet	Once daily in the evening		23
	Pediatric (2 to 5 years)	One 4-mg chewable tablet or one 4-mg packet of oral granules	Once daily in the evening		23
	Pediatric (12 to 23 months)	One 4-mg packet of oral granules	Once daily in the evening	Safety/efficacy <12 months not established.	26
Exercise-Induced Bronchoconstriction (EIB) Prevention	Adults & Adolescents (≥15 years)	One 10-mg film-coated tablet	At least 2 hours before exercise	Do not take an additional dose within 24 hours. If already taking daily for another indication, do not take an extra dose for EIB.	23
	Pediatric (6 to 14 years)	One 5-mg chewable tablet	At least 2 hours before exercise	Safety/efficacy <6 years not established.	23
Seasonal Allergic Rhinitis (SAR)	Adults & Adolescents (≥15 years)	One 10-mg film-coated tablet	Once daily	Time of administration can be individualized (morning or evening). For patients with both asthma and AR, take once daily in the evening.	23
	Pediatric (6 to 14 years)	One 5-mg chewable tablet	Once daily		23
	Pediatric (2 to 5 years)	One 4-mg chewable tablet or one 4-mg packet of oral granules	Once daily	Safety/efficacy <2 years not established.	23
Perennial Allergic Rhinitis (PAR)	Adults & Adolescents (≥15 years)	One 10-mg film-coated tablet	Once daily	Time of administration can be individualized. For patients with both asthma and AR, take once daily in the evening.	23
	Pediatric (6 to 14 years)	One 5-mg chewable tablet	Once daily		23
	Pediatric (2 to 5 years)	One 4-mg chewable tablet or one 4-mg packet of oral granules	Once daily		23
	Pediatric (6 to 23 months)	One 4-mg packet of oral granules	Once daily	Safety/efficacy <6 months not established.	25

VII. Industrial Synthesis and Commercial Profile

The journey of Montelukast from a laboratory discovery to a blockbuster pharmaceutical product is a compelling illustration of the evolution of industrial process chemistry and the economic lifecycle of a major drug.

A. Process Chemistry and Industrial Synthesis

The synthesis of the complex Montelukast molecule on an industrial scale presented significant chemical challenges. The central and most crucial step in its construction is the formation of the thioether bond (a C-S bond), which links the two principal fragments of the molecule in a process known as thiolation.[62]

Early Patented Routes

The initial synthetic routes, such as the one detailed in Merck's U.S. Patent No. 5,614,632, established the fundamental strategy. This process began with a complex chiral diol intermediate, 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxypropyl)phenyl)-2-propanol.[64] The key steps were:

1. Activation: The secondary hydroxyl group on the diol was converted into a better leaving group to facilitate the subsequent substitution reaction. This was typically achieved by reacting it with methanesulfonyl chloride to form a mesylate intermediate.[64]
2. Coupling: The resulting mesylate compound was then coupled with the second key building block, the thiol-containing 1-(mercaptomethyl)cyclopropaneacetic acid.[63]

Challenges and Process Optimization

While chemically sound, these early industrial syntheses were fraught with challenges that made large-scale production difficult and costly:

• Harsh Reaction Conditions: The mesylation step often required cryogenic temperatures, typically between -25°C and -35°C, which are energy-intensive and difficult to maintain consistently in large industrial reactors.[64]
• Use of Hazardous Reagents: The coupling step frequently relied on the use of n-Butyl lithium, a highly pyrophoric (ignites spontaneously in air) and hazardous reagent, to generate the reactive dilithium salt of the thiol. This necessitated strictly anhydrous (water-free) conditions and posed significant safety risks.[8]
• Unstable Intermediates: The mesylate intermediate itself was found to be highly unstable under normal atmospheric conditions, requiring continuous storage at temperatures below -15°C to prevent degradation.[65]
• Purification Difficulties: Initial processes often yielded the final product as an oily substance, which necessitated purification by column chromatography—a technique that is inefficient and impractical for multi-ton industrial production. A significant breakthrough in the original process was the development of a method to purify crude Montelukast by forming a crystalline salt with dicyclohexylamine. This allowed for highly effective purification via simple recrystallization, circumventing the need for chromatography.[63]

The immense commercial success of Singulair, which became a multi-billion dollar per year drug, created a powerful economic incentive to overcome these manufacturing hurdles.[67] This drove a wave of innovation in process chemistry, reflected in numerous subsequent patents and research publications describing "improved," "scalable," and more "efficient" synthetic routes.[62] This subsequent research focused specifically on developing syntheses that avoided hazardous reagents like n-BuLi, operated at more moderate temperatures, utilized more stable intermediates, and minimized the formation of impurities.[62] Key innovations included the use of phase-transfer catalysts (e.g., polyethers) to improve reaction selectivity, the deployment of novel homogeneous metal-based catalysts (e.g., palladium catalysts for Mizoroki-Heck reactions) to form key C-C bonds more efficiently, and the development of highly selective biocatalytic (enzymatic) reduction steps that offered superior performance and stereoselectivity compared to traditional chemical methods.[62] The synthetic history of Montelukast thus serves as a classic case study in the evolution of pharmaceutical process chemistry, demonstrating the critical journey from a complex laboratory synthesis to a robust, safe, and economically viable industrial manufacturing process.

B. Commercial and Patent History

• Originator and Brand Name: Montelukast was discovered and developed by Merck Frosst Canada and was marketed globally by Merck & Co. under the highly successful brand name Singulair.[2]
• Regulatory Approval: It was first approved by the US FDA on February 20, 1998.[3] Approvals in major European markets followed shortly thereafter, solidifying its status as a global product.[72]
• Patent Expiry and Generic Competition: The primary U.S. patent protecting the Montelukast compound (U.S. Patent No. 5,565,473) expired on August 3, 2012.[8] This date marked a significant "patent cliff" event for Merck, which anticipated a substantial and rapid decline in revenue from one of its top-selling drugs.[75] On the very day the patent expired, the FDA granted marketing approval to multiple pharmaceutical companies for generic versions of Montelukast, including Teva Pharmaceuticals, Aurobindo Pharma, Glenmark, and Dr. Reddy's Laboratories, ushering in an era of widespread generic competition.[11] While subsequent patents covering specific formulations, such as the oral granules (U.S. Patent No. 8,007,830, expired in October 2022), provided extended protection for those dosage forms, the expiry of the main compound patent was the pivotal event that opened the market to generics.[79]

VIII. Conclusion and Expert Recommendations

Montelukast stands as a significant yet paradoxical therapeutic agent in the modern pharmacopeia. Its development represents a success in rational drug design, with its targeted antagonism of the CysLT1 receptor providing an effective and well-understood mechanism for controlling the inflammatory pathways central to asthma and allergic rhinitis. The convenience of its oral, once-daily formulation has secured it an important clinical niche, particularly as an alternative for patients who struggle with adherence to inhaled therapies or for whom specific asthma phenotypes make it a logical choice.

This clinical utility, however, is fundamentally overshadowed by the serious and unpredictable risk of neuropsychiatric adverse events. The global regulatory actions, culminating in Boxed Warnings from the FDA and EMA, confirm that this risk is not a minor consideration but a central and defining feature of the drug's safety profile. The potential for severe and lasting harm, including suicidality, has permanently altered the risk-benefit calculus for Montelukast. This is especially true for its use in non-life-threatening conditions like mild allergic rhinitis, for which a multitude of safer alternatives are readily available.

Based on a comprehensive review of the available evidence, the following expert recommendations are provided to guide the safe and appropriate clinical use of Montelukast:

1. Prioritize Rigorous Informed Consent: Clinicians have a critical ethical and legal obligation to conduct a thorough discussion of the potential neuropsychiatric risks with every patient or their caregiver before initiating therapy. This conversation must cover the full spectrum of possible mood and behavioral changes, from agitation and depression to suicidal thoughts. The discussion should be clearly documented, and the patient-facing Medication Guide must be provided and reviewed to ensure comprehension.
2. Strict Adherence to Indication-Specific Risk-Benefit Assessment: The use of Montelukast must be guided by a careful, indication-specific evaluation of its risks and benefits. In alignment with FDA guidance, Montelukast should not be considered a first-line agent for mild allergic rhinitis. Its use in this context should be strictly reserved for the small subset of patients who have failed or are intolerant to all other standard therapies (e.g., second-generation antihistamines, intranasal corticosteroids).
3. Careful Patient Selection for Asthma: While Montelukast remains a valid therapeutic option for asthma, prescribers must carefully weigh the risk-benefit on an individual basis. A patient's psychiatric history and baseline mental health status should be considered. It remains a valuable tool for patients with documented, insurmountable adherence challenges with ICS, significant steroid phobia, or specific leukotriene-driven phenotypes like AERD, but the potential for neuropsychiatric harm must always be part of the decision-making process.
4. Implement Vigilant Monitoring: All patients prescribed Montelukast, with a particular emphasis on children and adolescents, must be actively monitored for the emergence of any new or worsening neuropsychiatric symptoms. Clinicians should proactively inquire about sleep disturbances, mood swings, anxiety, depression, and other behavioral changes at every follow-up visit.
5. Establish a Clear Discontinuation Protocol: Patients and their families must be explicitly instructed to stop taking Montelukast immediately and contact their healthcare provider if any concerning neuropsychiatric symptoms occur. They should be aware that some symptoms may persist even after the drug is discontinued and that follow-up is necessary.
6. Conduct Thorough Medication Reconciliation: Given the potential for clinically significant drug-drug interactions mediated by its metabolism through CYP enzymes, a comprehensive review of a patient's concomitant medications is essential. Co-prescription with potent inhibitors (e.g., gemfibrozil) or inducers (e.g., rifampicin, phenobarbital) of its metabolic pathways should be avoided or managed with extreme caution to prevent alterations in Montelukast exposure that could negatively impact its safety or efficacy.

Works cited

1. Montelukast | C35H36ClNO3S | CID 5281040 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Montelukast
2. Montelukast | 158966-92-8 - ChemicalBook, accessed July 15, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7112818.htm
3. Montelukast: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 15, 2025, https://go.drugbank.com/drugs/DB00471
4. Montelukast (MK-476, CAS Number: 158966-92-8) | Cayman Chemical, accessed July 15, 2025, https://www.caymanchem.com/product/35779/montelukast
5. Montelukast | 158966-92-8 | FM137467 - Biosynth, accessed July 15, 2025, https://www.biosynth.com/p/FM137467/158966-92-8-montelukast
6. SINGULAIR® - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020829s035,020830s037,021409s015lbl.pdf
7. SINGULAIR® - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020829s38,020830s40,021409s018lbl.pdf
8. Montelukast Sodium | New Drug Approvals, accessed July 15, 2025, https://newdrugapprovals.org/tag/montelukast-sodium/
9. Montelukast | 158966-92-8 - Sigma-Aldrich, accessed July 15, 2025, https://www.sigmaaldrich.com/US/en/product/ambeedinc/ambh96f10a90
10. Data Sheet – Montelukast Viatris – 23-May-2024 - Medsafe, accessed July 15, 2025, https://www.medsafe.govt.nz/profs/datasheet/m/MontelukastMylanTab.pdf
11. Montelukast - Wikipedia, accessed July 15, 2025, https://en.wikipedia.org/wiki/Montelukast
12. Montelukast | CAS#158966-92-8 | leukotriene receptor antagonist - MedKoo Biosciences, accessed July 15, 2025, https://www.medkoo.com/products/20580
13. Singulair (Montelukast Sodium) - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s051_020830s052_021409s028lbl.pdf
14. Montelukast: A Scientific and Legal Review - JAPI, accessed July 15, 2025, https://japi.org/article/japi-73-5-70
15. Montelukast and zafirlukast in asthma | Drug and Therapeutics Bulletin, accessed July 15, 2025, https://dtb.bmj.com/content/36/9/65
16. montelukast sodium tablet, chewable SINGULAIR - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020829s049,020830s051,021409s027lbl.pdf
17. Anti-enzymatic and DNA docking studies of montelukast: A multifaceted molecular scaffold with in vitro investigations, molecular expression analysis and molecular dynamics simulations, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10828691/
18. Montelukast - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 15, 2025, https://www.pediatriconcall.com/drugs/montelukast/782
19. Clinical effectiveness and safety of montelukast in asthma. What are t - Dove Medical Press, accessed July 15, 2025, https://www.dovepress.com/clinical-effectiveness-and-safety-of-montelukast-in-asthma-what-are-th-peer-reviewed-fulltext-article-DDDT
20. Montelukasts - Mechanism of Action - YouTube, accessed July 15, 2025, https://www.youtube.com/watch?v=iTcZWrVd0nM
21. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/8692739/
22. Montelukast (Singulair): Uses & Warnings - Cleveland Clinic, accessed July 15, 2025, https://my.clevelandclinic.org/health/drugs/20684-montelukast-tablets
23. Singulair (montelukast) dosing, indications, interactions, adverse effects, and more, accessed July 15, 2025, https://reference.medscape.com/drug/singulair-montelukast-343440
24. Montelukast - StatPearls - NCBI Bookshelf, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459301/
25. Singulair (montelukast sodium) tablet label - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021409s036lbl.pdf
26. SERIOUS NEUROPSYCHIATRIC EVENTS See full prescribing information for complete boxed warning. - DailyMed, accessed July 15, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=da038cf6-cfad-43a4-ab8e-d81d028d6087&type=display
27. Montelukast: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed July 15, 2025, https://www.drugs.com/montelukast.html
28. Montelukast: MedlinePlus Drug Information, accessed July 15, 2025, https://medlineplus.gov/druginfo/meds/a600014.html
29. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis, accessed July 15, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug
30. HIGHLIGHTS OF PRESCRIBING INFORMATION - FDA, accessed July 15, 2025, https://www.fda.gov/media/131036/download
31. New Warnings on Singulair Allergy and Asthma Drug - National Center for Health Research, accessed July 15, 2025, https://www.center4research.org/new-warnings-on-singulair-allergy-and-asthma-drug/
32. Montelukast versus inhaled corticosteroids in the management of ..., accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3436659/
33. Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? | Allergologia et Immunopathologia - Elsevier, accessed July 15, 2025, https://www.elsevier.es/en-revista-allergologia-et-immunopathologia-105-articulo-montelukast-versus-inhaled-corticosteroids-as-S0301054609702484
34. Inhaled Corticosteroids May Be Superior to Montelukast in Children With Asthma, accessed July 15, 2025, https://www.medscape.org/viewarticle/713576
35. Montelukast in the treatment of asthma and allergic rhinitis - Open Access Journals, accessed July 15, 2025, https://www.openaccessjournals.com/articles/montelukast-in-the-treatment-of-asthmaand-allergic-rhinitis.pdf
36. Montelukast in the management of allergic rhinitis - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1936314/
37. Loratadine vs Montelukast Comparison - Drugs.com, accessed July 15, 2025, https://www.drugs.com/compare/loratadine-vs-montelukast
38. Montelukast vs Zyrtec Comparison - Drugs.com, accessed July 15, 2025, https://www.drugs.com/compare/montelukast-vs-zyrtec
39. Economic Evaluation of Quality-of-Life Improvement with Second-Generation Antihistamines and Montelukast in Patients with Allergic Rhinitis - American Health & Drug Benefits, accessed July 15, 2025, https://www.ahdbonline.com/articles/feature-134
40. Cost-Effectiveness of Second-Generation Antihistamines and Montelukast in Relieving Allergic Rhinitis Nasal Symptoms - American Health & Drug Benefits, accessed July 15, 2025, https://www.ahdbonline.com/issues/2008/october-2008-vol-1-no-8/feature-299
41. Montelukast helps chronic urticaria - The BMJ, accessed July 15, 2025, https://www.bmj.com/content/326/7381/0.8
42. Montelukast: Chronic Urticaria - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4589848/
43. The Addition of Montelukast for the Treatment of Chronic Idiopathic Urticaria - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8327886/
44. Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis | Acta Dermato-Venereologica, accessed July 15, 2025, https://medicaljournalssweden.se/actadv/article/view/43140/50291
45. Leukotriene Receptor Antagonists for the Treatment of Allergic Skin Disorders - AAFP, accessed July 15, 2025, https://www.aafp.org/pubs/afp/issues/2008/0701/p112.html
46. Study Details | The Effectiveness of Montelukast on Atopic Dermatitis in Koreans, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT00903357
47. From the Cochrane Library: Leukotriene Receptor Antagonists for Eczema - JMIR Dermatology, accessed July 15, 2025, https://derma.jmir.org/2024/1/e50434/PDF
48. From the Cochrane Library: Leukotriene Receptor Antagonists for Eczema, accessed July 15, 2025, https://derma.jmir.org/2024/1/e50434/
49. www.psychiatrist.com, accessed July 15, 2025, https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/#:~:text=Montelukast%20has%20many%20other%20off,acne%2C%20and%20obstructive%20sleep%20apnea.
50. Two Cases of Montelukast-Associated Psychosis in Children - Psychiatrist.com, accessed July 15, 2025, https://www.psychiatrist.com/pcc/montelukast-associated-psychosis-children/
51. Montelukast: New boxed warning to raise further awareness of the risk of neuropsychiatric events - HPRA, accessed July 15, 2025, https://assets.hpra.ie/data/docs/default-source/product-updates/mims_imf/montelukast-boxed-warning---mims---nov-2023.pdf?sfvrsn=3cb45cee_3
52. FDA warning montelukast 03.2020-Statement of the Austrian working group of pediatric pulmonology and allergology - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/34904177/
53. Montelukast - Singulair - Asthma & Allergy Foundation of America, accessed July 15, 2025, https://aafa.org/asthma-medicine/montelukast-singulair/
54. Answer given by Ms Kyriakides on behalf of the European Commission, accessed July 15, 2025, https://www.europarl.europa.eu/doceo/document/E-9-2023-002177-ASW_EN.html
55. MHRA reviewing safety of asthma drug as Yellow Card reports increase, accessed July 15, 2025, https://pharmaceutical-journal.com/article/news/mhra-reviewing-safety-of-asthma-drug-as-yellow-card-reports-increase
56. Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning - Due to Restricting Use for Allergic Rhinitis | FDA, accessed July 15, 2025, https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use
57. Taking montelukast with other medicines and herbal supplements - NHS, accessed July 15, 2025, https://www.nhs.uk/medicines/montelukast/taking-montelukast-with-other-medicines-and-herbal-supplements/
58. Montelukast Interactions Checker - Drugs.com, accessed July 15, 2025, https://www.drugs.com/drug-interactions/montelukast.html
59. my.clevelandclinic.org, accessed July 15, 2025, https://my.clevelandclinic.org/health/drugs/20684-montelukast-tablets#:~:text=It%20decreases%20inflammation%20in%20your,this%20medication%20is%20Singulair%C2%AE.
60. Montelukast (oral route) - Mayo Clinic, accessed July 15, 2025, https://www.mayoclinic.org/drugs-supplements/montelukast-oral-route/description/drg-20064902
61. Singulair Interactions Checker - Drugs.com, accessed July 15, 2025, https://www.drugs.com/drug-interactions/montelukast,singulair.html
62. Improved Process for the Preparation of Montelukast: Development of an Efficient Synthesis, Identification of Critical Impurities and Degradants - Bohrium, accessed July 15, 2025, https://www.bohrium.com/paper-details/improved-process-for-the-preparation-of-montelukast-development-of-an-efficient-synthesis-identification-of-critical-impurities-and-degradants/811806917058887681-3492
63. Improved Process for the Preparation of Montelukast: Development ..., accessed July 15, 2025, https://pubs.acs.org/doi/10.1021/op900311z
64. WO2014001860A1 - Process for preparation of montelukast sodium - Google Patents, accessed July 15, 2025, https://patents.google.com/patent/WO2014001860A1/en
65. WO2006008751A2 - Process for the preparation of montelukast and its salts - Google Patents, accessed July 15, 2025, https://patents.google.com/patent/WO2006008751A2/en
66. Process for preparation of montelukast sodium - Eureka | Patsnap, accessed July 15, 2025, https://eureka.patsnap.com/patent-US20150299127A1
67. An Enantioselective Formal Synthesis of Montelukast Sodium - ACS Publications, accessed July 15, 2025, https://pubs.acs.org/doi/10.1021/acs.joc.5b00197
68. Improved Process for the Preparation of Montelukast: Development of an Efficient Synthesis, Identification of Critical Impurities and Degradants - ACS Publications, accessed July 15, 2025, https://pubs.acs.org/doi/abs/10.1021/op900311z
69. WO2007012075A2 - Preparation of montelukast - Google Patents, accessed July 15, 2025, https://patents.google.com/patent/WO2007012075A2/en
70. Synthesis of Montelukast - Thieme Connect, accessed July 15, 2025, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1219648.pdf
71. Drug Approval Package: Singulair (Montelukast Sodium) NDA# 020829 - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020829s000_SingulairTOC.cfm
72. Montelukast and Nightmares: Further Characterisation Using Data from VigiBase - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9189082/
73. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Montelukast Synthon 4 mg and 5 mg chewable tablets - Cbg-meb.nl, accessed July 15, 2025, https://db.cbg-meb.nl/pars/h108680.pdf
74. A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database - PubMed Central, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12220754/
75. FDA approves generic versions of Singulair | Drug Discovery News, accessed July 15, 2025, https://www.drugdiscoverynews.com/fda-approves-generic-versions-of-singulair-6427
76. Drug Patent Expirations and the “Patent Cliff” - U.S. Pharmacist, accessed July 15, 2025, https://www.uspharmacist.com/article/drug-patent-expirations-and-the-patent-cliff
77. Generic Singulair Availability - Drugs.com, accessed July 15, 2025, https://www.drugs.com/availability/generic-singulair.html
78. FDA Approves Generic Singulair - Drug Discovery and Development, accessed July 15, 2025, https://www.drugdiscoverytrends.com/fda-approves-generic-singulair/
79. Singulair patent expiration - Pharsight, accessed July 15, 2025, https://pharsight.greyb.com/drug/singulair-patent-expiration
80. Pharmaceutical drugs covered by patent 8,007,830. Claims, international patent equivalents, patent expiration dates, and freedom to operate - DrugPatentWatch, accessed July 15, 2025, https://www.drugpatentwatch.com/p/patent/8007830